top of page
Home: Welcome

Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2021, moving towards broad patient access to cancer-defeating cures."
Dr. Daniel Teper,
Cytovia Therapeutics CEO
CYTOVIA IN THE NEWS
We'd love to hear from you

February 16th, 2021

bottom of page